SCHEMBL2429185

SCHEMBL2429185

Fc1c(-c2ccc(-c3cnco3)cc2)nc2ccc(I)cn12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.40
▸ PKM P14618 2/20 0.40
▸ NOTUM Q6P988 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ PTK2 Q05397 1/20 0.39
▸ KEAP1 Q14145 1/20 0.38
▸ CYP11B1 P15538 2/20 0.37
▸ CYP11B2 P19099 2/20 0.37
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ LTA4H P09960 1/20 0.35
▸ TGFBR1 P36897 1/20 0.33
▸ TGFBR2 P37173 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ KMT2A Q03164 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2430192 0.77 CYP3A4 (0.43) LMNAPKMNOTUMGAAPTK2
SCHEMBL2429956 0.73 APP (0.56) LMNAPKMNOTUMGAAPTK2
SCHEMBL10187964 0.72 PKM (0.64) LMNAPKMNOTUMGAAPTK2
SCHEMBL2906472 0.68 GABRA1 (0.42) CYP11B1CYP11B2KDM4ENPC1ALDH1A1
SCHEMBL10768177 0.67 PKM (0.78) LMNAPKMNOTUMGAAPTK2
SCHEMBL2817090 0.66 CYP11B1 (0.53) CYP11B1CYP11B2KDM4ENPC1ALDH1A1
SCHEMBL3635051 0.66 PKM (0.64) LMNAPKMNOTUMGAAPTK2
SCHEMBL2432402 0.65 APP (0.56) LMNAPKMNOTUMGAAPTK2
SCHEMBL12291867 0.65 APP (0.56) LMNAPKMNOTUMGAAPTK2
SCHEMBL13667800 0.62 PKM (0.58) LMNAPKMNOTUMGAAPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 — — EP claimed
EP-1956013-B1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO LTD (JP) 2016-04-13 — — EP disclosed
US-8022075-B2 Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition FUJIFILM RI PHARMA CO., LTD. (JP) 2011-09-20 — — US disclosed
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION FUJIFILM RI PHARMA CO., LTD. (JP) 2009-06-25 — — US disclosed
EP-1956013-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION Fujifilm RI Pharma Co., Ltd. (JP) 2008-08-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162283-A1 DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION APP, TTR, BACE1 LMNA 1272/4885PKM 2337/4885NOTUM 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback